Lineage W introduces a single build for the global market to create a global battle community. NCSoft CCO Taek Jin Kim marked this game as the final Lineage. Later, NCsoft has updated the website to reveal more information and open for pre-registration. Targeted for worldwide launch with most platforms supported. *Includes all descendent lineages.The week before THE WORLD showcase events, NCSoft announced for new Lineage game that will be set to the largest launching title ever. ***additional mutation outside the spike protein: ORF1a:S1221L, ORF1a:P1640S, ORF1a:N4060S ORF1b:G662S E:T11A **additional mutation outside the spike protein: ORF1a:S2519P §these lineages have identical constellation of mutations in the spike and the following differences outside the spike: BA.2.9.1: ORF1a: K322R, ORF3a:H78Y, N: P67S, N: S412I # these lineages have identical constellation of mutations in the spike and the following differences outside the spike: BA.4: ORF7b:L11F, N:P151S ORF6:D61L, ORF1a:del141/143 BA.5: M:D3N. If this evidence arises, WHO will decide, in consultation with the TAG-VE, if designation of the emerging variant warrants a separate WHO label. *these subvariants are tracked under Omicron unless/until sufficient evidence arises that the virus characteristics are substantially different from what is known about the VOC they belong to. If any of these lineages is proven to have distinct characteristics as compared to the original VOC it belongs to, the TAG-VE will convene and may advice WHO to give it a separate WHO label.īA.2-like constellation in the spike protein + S:del69/70, S:L452R, S:F486V, S:Q493R reversionīA.2 + S:K147E, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion The main objective of this category is to investigate if these lineages may pose an additional threat to global public health as compared to other circulating viruses. In light of the widespread transmission of the Omicron VOC across the globe and the subsequent expected increased viral diversity, WHO has added a new category to its variant tracking system, termed “Omicron subvariants under monitoring' to signal to public health authorities globally, which VOC lineages may require prioritized attention and monitoring. Each constellation may or may not differ in the public health risk it poses, and each lineage that includes substitutions in key sites may need further investigation to assess whether its characteristics diverge or not from those that define the variant of concern they stem from. Since its designation as a VOC by WHO on 26 November 2021, viruses part of the Omicron complex have continued to evolve, leading to descendent lineages with different genetic constellations of mutations. As transmission of these VOCs has been sustained, this has led to significant intra-VOC evolution. Delta reached almost 90% of all viral sequences submitted on GISAID by October 2021, and Omicron is currently the dominant variant circulating globally, accounting for >98% of viral sequences shared on GISAID after February 2022. Latest VOCs have largely replaced other co-circulating SARS-CoV-2 variants. At the present time, this expert group convened by WHO has recommended using letters of the Greek Alphabet, i.e., Alpha, Beta, Gamma, Delta which will be easier and more practical to be discussed by non-scientific audiences. When using this naming scheme and referring to the genomic sequence of SARS-CoV-2 identified from the first cases (December 2019), the term ‘index virus’ should be used. To assist with public discussions of variants, WHO convened a group of scientists from the WHO Virus Evolution Working Group (now called the Technical Advisory Group on Virus Evolution), the WHO COVID-19 reference laboratory network, representatives from GISAID, Nextstrain, Pango and additional experts in virological, microbial nomenclature and communication from several countries and agencies to consider easy-to-pronounce and non-stigmatising labels for VOI and VOC. The established nomenclature systems for naming and tracking SARS-CoV-2 genetic lineages by GISAID, Nextstrain and Pango are currently and will remain in use by scientists and in scientific research.

Lineage w na